Evogene (EVGN)
NASDAQ:EVGN
Top Page
Evogene
(NASDAQ:EVGN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.86
▼(-22.18% Downside)
Action:ReiteratedDate:03/14/26
The score is held down primarily by weak financial performance (persistent losses, heavy cash burn, negative equity, and declining revenue). Technicals also reflect a downtrend with negative momentum. The earnings call provides partial support through sustained cost cuts and near-term liquidity actions, but top-line weakness and one-time items keep overall risk elevated.
Positive Factors
Strategic refocus on ChemPass AI and core markets
Management narrowed focus to one proprietary engine and two high-impact markets, concentrating R&D and BD resources. That streamlining and divestiture of noncore assets improves capital efficiency and increases the likelihood that limited cash is allocated to commercially scalable programs over the next 2–6 months.
Negative Factors
Consistent negative cash flow and weakened equity base
Persistent negative operating and free cash flow, combined with stockholders' equity turning negative in 2024, materially limit financial flexibility. Even with narrower cash burn in 2025, the company remains reliant on external financing and asset sales to fund operations beyond the stated ~1.5 year runway.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic refocus on ChemPass AI and core markets
Management narrowed focus to one proprietary engine and two high-impact markets, concentrating R&D and BD resources. That streamlining and divestiture of noncore assets improves capital efficiency and increases the likelihood that limited cash is allocated to commercially scalable programs over the next 2–6 months.
Read all positive factors
Evogene (EVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.14M
Dividend YieldN/A
Average Volume (3M)115.16K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-29.78%
EPS Growth88.96%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding8,718,193
10 Day Avg. Volume235,429
30 Day Avg. Volume115,158
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-105.63
Price to Sales (P/S)2.25
P/FCF Ratio-0.64
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-0.87
Enterprise Value/Gross Profit-6.49
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$1.75Price Target Upside59.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$2.15M
Evogene Business Overview & Revenue Model
Company Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Co...
How the Company Makes Money
null...
Evogene Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Neutral
The call presents a balanced mix of positive strategic and operational developments and significant near-term financial and operational challenges. Positives include a clear strategic refocus on ChemPass AI, strong technical milestones (38 billion-molecule foundation model, 90% design precision), new automation collaboration with Google Cloud, key partnerships (Bayer, Corteva) and material reductions in operating costs that improved annual operating and net losses substantially. Negatives include meaningful revenue declines (≈30% year-over-year and ≈80% in Q4), a large inventory impairment (~$2.2M) that drove higher cost of revenues, a sharp reduction in financing income (~85% year-over-year), a deteriorating Q4 operating/net loss profile, and modest cash balances reliant in part on one-time discontinued-operations proceeds and future collaboration or financing catalysts. Overall, the strategic and technical progress is offset by current top-line weakness and one-time impairment impacts, leading to a balanced view of prospects and risks.Positive Updates
Strategic Refocus on ChemPass AI and High-Impact Markets
Company completed a strategic transformation to concentrate on a single computational engine, ChemPass AI, and two markets (human health small-molecule drugs and agriculture ag-chemicals), streamlining organization, divesting noncore assets and aligning business development to the refined strategy.
Negative Updates
Revenue Decline Year-over-Year and Sharp Q4 Drop
Total revenues for 2025 were ~$3.9M versus ~$5.6M in 2024, a decrease of ~$1.7M (~30% decline). Q4 revenues fell to ~$0.3M from ~$1.5M in the prior-year quarter (≈80% decline), primarily due to reduced AgPlenus/Casterra seed sales and fewer one-time 2024 payments.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Refocus on ChemPass AI and High-Impact Markets
Company completed a strategic transformation to concentrate on a single computational engine, ChemPass AI, and two markets (human health small-molecule drugs and agriculture ag-chemicals), streamlining organization, divesting noncore assets and aligning business development to the refined strategy.
Read all positive updates
Company Guidance
The company guided that its lower cost structure will be sustained, citing operating expenses net of approximately $13.8M for 2025 (down from ~$22M in 2024) and fourth‑quarter operating expenses of ~$3.2M (vs. ~$4.3M in Q4 2024); consolidated cash, cash equivalents and short‑term deposits were about $13M as of 12/31/2025 with consolidated cash usage of ~ $3M in Q4 2025 (and ~$2.4M excluding Lavie Bio and Biomica), and management said cash after expected Lavie Bio/Biomica distributions should cover needs to at least mid‑next year (or “a little more than 1.5 years” without additional transactions); Feb 2026 warrant inducement brought gross proceeds of ~ $3.4M and issued new warrants to purchase up to 5,076,924 shares exercisable at $1.25; 2025 revenue was ~ $3.9M (down ~$1.7M from $5.6M), Q4 revenue ~$0.3M (vs. $1.5M), cost of revenues ~$4.1M (including a ~$2.2M Casterra inventory impairment), Q4 cost of revenues $2.3M, R&D net ~$8M (vs. $12.5M), S&M ~$1.5M (vs. $2M), G&A ~$4.3M (vs. $7M), operating loss ~$14M (vs. $18.8M) and 2025 net loss ~$7.8M (vs. $18.1M), while discontinued‑operations produced income of ~$5.7M (including a ~$6.4M gain on sale); on the technology side they cited ChemPass AI trained on a 38‑billion‑molecule universe and delivering ~90% design precision, positioning expected near‑term catalysts from further tech and pharma/ag collaborations.Evogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.85M | 8.51M | 5.64M | 1.68M | 930.00K |
| Gross Profit | 795.00K | 3.39M | 1.40M | -1.77M | -2.07M |
| EBITDA | -12.85M | -15.38M | -23.20M | -26.93M | -27.80M |
| Net Income | -8.48M | -16.48M | -23.88M | -26.64M | -27.79M |
Balance Sheet | |||||
| Total Assets | 20.05M | 39.86M | 51.10M | 56.13M | 76.30M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 15.31M | 31.06M | 35.35M | 53.87M |
| Total Debt | 2.20M | 12.87M | 11.51M | 11.93M | 2.67M |
| Total Liabilities | 5.00M | 25.03M | 22.42M | 21.34M | 12.88M |
| Stockholders Equity | -82.00K | -1.45M | 12.05M | 27.93M | 53.65M |
Cash Flow | |||||
| Free Cash Flow | -13.64M | -20.33M | -22.36M | -24.85M | -25.56M |
| Operating Cash Flow | -13.50M | -19.70M | -21.58M | -23.68M | -24.84M |
| Investing Cash Flow | 17.74M | 9.62M | -4.54M | 13.27M | -20.44M |
| Financing Cash Flow | -6.60M | 4.66M | 18.15M | 9.34M | 30.28M |
Evogene Technical Analysis
Negative
1.10
Price Trends
0.89
Negative
0.99
Negative
1.13
Negative
Market Momentum
-0.02
Negative
48.28
Neutral
33.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.89, and below the 200-day MA of 1.13, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVGN.
Evogene Risk Analysis
Evogene disclosed 62 risk factors in its most recent earnings report. Evogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $109.05M | -0.65 | -116.86% | ― | -98.25% | 63.05% | |
47 Neutral | $9.19M | -0.31 | -97.58% | ― | -46.88% | 34.83% | |
45 Neutral | $72.89M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
44 Neutral | $7.14M | -1.02 | 553.15% | ― | -29.78% | 88.96% | |
41 Neutral | $4.75M | -3.61 | -154.50% | ― | ― | 54.25% | |
39 Underperform | $370.80K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
EVGN
Evogene
0.82
-0.23
-22.00%
IBIO
Ibio
2.11
0.91
75.83%
KZIA
Kazia Therapeutics
9.62
6.15
177.23%
WINT
Windtree Therapeutics
0.01
-1.29
-99.15%
PHGE
BiomX
2.98
-7.66
-71.99%
BOLT
Bolt Biotherapeutics
4.78
-1.42
-22.90%
Evogene Corporate Events
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul
Mar 5, 2026
On March 5, 2026, Evogene reported its fourth-quarter and full-year 2025 results, highlighting a strategic overhaul that consolidated the business around its ChemPass AI engine for small-molecule discovery in pharma and agriculture and exited non-...
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets
Feb 25, 2026
On February 25, 2026, Evogene released a CEO letter to shareholders outlining a strategic transformation undertaken in 2025 to sharpen its focus and capital allocation. The company consolidated technology development around its ChemPass AI™ ...
Evogene Secures $3.4 Million Through Warrant Inducement Deal
Feb 11, 2026
On February 10, 2026, Evogene entered into a warrant inducement agreement with an existing institutional investor, leading to the immediate cash exercise of August 2024 Series A and Series B warrants for 3,384,616 ordinary shares at a reduced pric...
Evogene’s Biomica Grants Lishan Biotech Global Rights to Microbiome Cancer Drug BMC128
Feb 4, 2026
On February 4, 2026, Evogene announced that its microbiome-focused subsidiary Biomica has signed an exclusive worldwide licensing deal with Shanghai-based clinical-stage biotech firm Lishan Biopharmaceuticals for BMC128, a first-in-class microbiom...
Evogene Announces CFO Resignation and Finance Leadership Transition
Jan 15, 2026
On January 15, 2026, Israel-based Evogene Ltd. reported a senior management change, announcing that Chief Financial Officer Yaron Eldad has submitted his resignation for personal reasons, effective March 31, 2026, with the company clarifying that ...
Evogene Appoints Dr. Olga Nissan as Vice President of Business Development to Drive AI-Driven Growth
Dec 30, 2025
On December 30, 2025, Israel-based Evogene Ltd. announced that it has appointed Dr. Olga Nissan as its Vice President of Business Development, effective January 1, 2026, marking a key addition to its leadership team. Dr. Nissan brings more than 15...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.